FHTX vs AUPH

For growth investors, Foghorn Therapeutics Inc.

(FHTX) is the stronger pick with 36. 8% revenue growth year-over-year, versus 20. 4% for Aurinia Pharmaceuticals Inc. (AUPH). Aurinia Pharmaceuticals Inc. (AUPH) offers the better valuation at 7. 4x trailing P/E (18. 7x forward), making it the more compelling value choice. Analysts rate Foghorn Therapeutics Inc. (FHTX) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Aurinia Pharmaceuticals Inc.

(AUPH) delivered a total return of +52. 3%, compared to -54. 8% for Foghorn Therapeutics Inc. (FHTX). Over 10 years, the gap is even starker: AUPH returned +511. 6% versus FHTX's -75. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Aurinia Pharmaceuticals Inc.

(AUPH) is the lower-risk stock at 0. 89β versus Foghorn Therapeutics Inc. 's 2. 07β — meaning FHTX is approximately 133% more volatile than AUPH relative to the S&P 500.

By revenue growth (latest reported year), Foghorn Therapeutics Inc.

(FHTX) is pulling ahead at 36. 8% versus 20. 4% for Aurinia Pharmaceuticals Inc. (AUPH). On earnings-per-share growth, the picture is similar: Aurinia Pharmaceuticals Inc. grew EPS 51. 7% year-over-year, compared to 25. 3% for Foghorn Therapeutics Inc.. Over a 3-year CAGR, AUPH leads at 28. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Aurinia Pharmaceuticals Inc.

(AUPH) is the more profitable company, earning 101. 5% net margin versus -240. 3% for Foghorn Therapeutics Inc. — meaning it keeps 101. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AUPH leads at 37. 1% versus -265. 6% for FHTX. At the gross margin level — before operating expenses — FHTX leads at 89. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for FHTX: 162.

8% to $11. 67.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Aurinia Pharmaceuticals Inc.

(AUPH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 89), +511. 6% 10Y return). Foghorn Therapeutics Inc. (FHTX) carries a higher beta of 2. 07 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AUPH: +511. 6%, FHTX: -75. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.